Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02605694
Title Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Age Groups: adult
Covered Countries USA

No variant requirements are available.